Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Day (March 2024)
24 slides from Novo Nordisk A/s Class B's investor day presentation, Mar 7, 2024
Slide 1: Diabetes care
Novo Nordisk® Diabetes care Camilla Sylvest EVP Commercial Strategy and Corporate Affairs Doug Langa EVP North America Operations Mike Doustdar EVP International Operations 7 MARCH Martin Holst Lange EVP Development ANNE SOFIE WEEKES HALD AND DAUGHTER Anne Sofie lives with type 1 diabetes Denmark
Slide 2: Forward-looking statements
2 Diabetes care Commercial execution and innovation Novo Nordisk® Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the statutory Annual Report 2023 and Form 20-F, which both were filed with the SEC in January 2024
Slide 3: Strategic aspirations 2025
3 Diabetes care Commercial execution and innovation Novo Nordisk® Strategic aspirations 2025 • Further raise the innovation bar for diabetes treatment therapeutic focus • Progress towards zero environmental impact • Develop a leading portfolio of superior treatment Innovation and • Being respected f
Slide 4: Diabetes is a serious chronic disease with increasing prevalence
4 Diabetes care Commercial execution and innovation Novo Nordisk® Diabetes is a serious chronic disease with increasing prevalence In 2045, 784 million adults are expected to live with diabetes T2D is associated with multiple comorbidities and mortality1 Million adults 1,000 1 in 10 have 1 in 8 have
Slide 5: Novo Nordisk is the global leader in the growing diabetes market
5 Diabetes care Commercial execution and innovation Novo Nordisk® Novo Nordisk is the global leader in the growing diabetes market Global diabetes care reported sales Volume growing ~5% with more people using GLP-1s and SGLT-2is DKK billion Novo Nordisk value market share1 33.8% Estimated prescripti
Slide 6: Innovation is the focus for strengthening leadership in diabetes
6 Diabetes care Commercial execution and innovation Novo Nordisk® Innovation is the focus for strengthening leadership in diabetes Approach to diabetes innovation Novo Nordisk’s product portfolio covers all three treatment segments Oral anti-diabetic Injectable GLP-1 Insulins Key products Icodec 1 O
Slide 7: Insulin icodec holds potential to be the insulin of choice
7 Diabetes care Commercial execution and innovation Novo Nordisk® Insulin icodec holds potential to be the insulin of choice for people living with type 2 diabetes starting basal insulin treatment Today’s global basal insulin market is sizeable The opportunity for insulin icodec bDKK Patient behavio
Slide 8: Semaglutide addresses many of the comorbidities associated with type 2 diabetes
8 Diabetes care Commercial execution and innovation Novo Nordisk® Semaglutide addresses many of the comorbidities associated with type 2 diabetes – with a potential of further additions Patient overlaps for key focus areas in type 2 diabetes Semaglutide has impact on several comorbidities Obesity UN
Slide 9: The use of GLP-1 treatments has accelerated in recent years
9 Diabetes care Commercial execution and innovation Novo Nordisk® The use of GLP-1 treatments has accelerated in recent years supported by innovation and guideline updates ~6% of total estimated diabetes prescriptions are for a GLP-1 - with large differences across markets Estimated monthly prescrip
Slide 10: North America Operations sales growth driven by GLP-1 treatments
10 Diabetes care Commercial execution and innovation Novo Nordisk® North America Operations sales growth driven by GLP-1 treatments Diabetes care sales in North America Operations US GLP-1 TRx Market share DKK billion Total GLP-1 TRx share (millions) Class growth1: >30% 120 6 60% 53% 96 5 50% 90 11
Slide 11: Novo Nordisk is the leader in the growing GLP-1 class
11 Diabetes care Commercial execution and innovation Novo Nordisk® Novo Nordisk is the leader in the growing GLP-1 class with stay time data on par with other chronic diseases Patient persistence on Ozempic® after 12 months1 Ozempic® is the key growth driver in NAO Patients on treatment (%) Novo Nor
Slide 12: Insulin icodec NAO regulatory decisions expected in 2024
12 Diabetes care Commercial execution and innovation Novo Nordisk® Insulin icodec NAO regulatory decisions expected in 2024 with ambition to be standard of care within the T2D basal segment US basal insulin market is 10 bDKK1 and competitive Focused on sustainable and broad patient access 19% % of v
Slide 13: Injectable and oral GLP-1s drive performance in International Operations
13 Diabetes care Commercial execution and innovation Novo Nordisk® Injectable and oral GLP-1s drive performance in International Operations Diabetes care sales and growth in International Operations GLP-1 patients and value market share in IO DKK billion Number of Value 100 prescriptions market shar
Slide 14: GLP-1 class remains less penetrated in International Operations
14 Diabetes care Commercial execution and innovation Novo Nordisk® GLP-1 class remains less penetrated relative to other modern type 2 diabetes treatments in International Operations People with diabetes in IO vs NN treated Modern non-insulin anti-diabetic Ozempic® and Rybelsus® driving IO growth Rx
Slide 15: International Operations utilises the broad and innovative insulin portfolio
15 Diabetes care Commercial execution and innovation Novo Nordisk® International Operations utilises the broad and innovative insulin portfolio 2023 Diabetes care sales composition in IO Broad insulin portfolio Future insulin launches in IO Once-weekly insulins Insulin icodec • IO basal insulin a 30
Slide 16: Development pipeline addresses unmet need in diabetes care (incretins)
16 Diabetes care Commercial execution and innovation Novo Nordisk® Development pipeline addresses unmet need in diabetes care by further raising the innovation bar Further raise the innovation bar Development pipeline 2024 2025 2026 2027 Our key focus areas FLOW, semaglutide 1 mg, CKD Submission STR
Slide 17: Development pipeline addresses unmet need in diabetes care (insulins)
17 Diabetes care Commercial execution and innovation Novo Nordisk® Development pipeline addresses unmet need in diabetes care by further raising the innovation bar Further raise the innovation bar Development pipeline 2024 2025 2026 2027 Our key focus areas Insulin icodec Regulatory decision2 OW bas
Slide 18: The FLOW trial was stopped early for efficacy and has now successfully completed
18 Diabetes care Commercial execution and innovation Novo Nordisk® The FLOW trial was stopped early for efficacy and has now successfully completed FLOW Trial Design n = 3,533 Semaglutide 1.0 mg + standard of care R Objective Evaluate the effect of OW semaglutide 1.0 mg vs 1:1 Placebo + standard of
Slide 19: Sema 1.0 mg demonstrates 24% reduction in kidney disease-related events
19 Diabetes care Commercial execution and innovation Novo Nordisk® Sema 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and CKD Primary endpoint Testing hierarchy of primary and secondary confirmatory endpoints Composite renal event HR [9
Slide 20: The STRIDE trial will add further evidence in 2024
20 Diabetes care Commercial execution and innovation Novo Nordisk® The STRIDE trial will add further evidence to the cardiometabolic- renal paradigm in 2024 Peripheral arterial disease is an atherosclerotic disease STRIDE trial design Atherosclerosis 800 patients with T2D and peripheral artery disea
Slide 21: CagriSema successfully completed phase 2 in type 2 diabetes
21 Diabetes care Commercial execution and innovation Novo Nordisk® CagriSema successfully completed phase 2 in type 2 diabetes, with a comprehensive phase 3 programme running CagriSema phase 2 data in type 2 diabetes – a 32-week trial in 92 people CagriSema differentiation potential in T2D • Improve
Slide 22: Amycretin will be tested in a phase 2 trial
22 Diabetes care Commercial execution and innovation Novo Nordisk® Amycretin will be tested in a phase 2 trial with oral and subcutaneous administration in people with type 2 diabetes Phase 2 amycretin trial design Objective ILLUSTRATIVE • Demonstrate the dose-response relationship of amycretin for
Slide 23: Successful completion of phase 1 GIP/GLP-1 trial in type 2 diabetes and obesity
23 Diabetes care Commercial execution and innovation Novo Nordisk® Successful completion of part 2 and 3 of the combined phase 1 GIP/GLP-1 trial in type 2 diabetes and obesity GIP/GLP-1 T2D MAD cohort in 24 people GIP/GLP-1 obesity MAD cohort in 31 people In the parts of the trial finalised GIP/GLP-
Slide 24: Closing remarks
Novo Nordisk® Closing remarks Number of people with diabetes continues to increase Innovation with GLP-1 treatments are driving the growth of the diabetes care market, yet only 6% of prescriptions Novo Nordisk has an extensive pipeline of innovative products including Insulin icodec, IcoSema, CagriS